

Official Transcript of Proceedings

NUCLEAR REGULATORY COMMISSION

Title: Advisory Committee on Reactor Safeguards
Non-Power Production and Utilization
Facilities Subcommittee: Open Session

Docket Number: (n/a)

Location: teleconference

Date: Wednesday, November 4, 2020

Work Order No.: NRC-1208

Pages 1-63

NEAL R. GROSS AND CO., INC.
Court Reporters and Transcribers
1323 Rhode Island Avenue, N.W.
Washington, D.C. 20005
(202) 234-4433

DISCLAIMER

UNITED STATES NUCLEAR REGULATORY COMMISSION'S
ADVISORY COMMITTEE ON REACTOR SAFEGUARDS

The contents of this transcript of the proceeding of the United States Nuclear Regulatory Commission Advisory Committee on Reactor Safeguards, as reported herein, is a record of the discussions recorded at the meeting.

This transcript has not been reviewed, corrected, and edited, and it may contain inaccuracies.

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS

1323 RHODE ISLAND AVE., N.W.

WASHINGTON, D.C. 20005-3701

(202) 234-4433

www.nealrgross.com

UNITED STATES OF AMERICA
 NUCLEAR REGULATORY COMMISSION

+ + + + +

ADVISORY COMMITTEE ON REACTOR SAFEGUARDS

(ACRS)

+ + + + +

NON-POWER PRODUCTION AND UTILIZATION FACILITIES

SUBCOMMITTEE

+ + + + +

WEDNESDAY

NOVEMBER 4, 2020

+ + + + +

The Subcommittee met via Teleconference,
 at 9:30 a.m. EST, Ronald G. Ballinger, Chairman,
 presiding.

COMMITTEE MEMBERS:

RONALD G. BALLINGER, Chairman

DENNIS BLEY, Member

CHARLES H. BROWN, JR. Member

VESNA B. DIMITRIJEVIC, Member

WALTER L. KIRCHNER, Member

JOSE MARCH-LEUBA, Chairman

DAVID A. PETTI, Member

JOY L. REMPE, Member

MATTHEW W. SUNSERI, Member

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
 1323 RHODE ISLAND AVE., N.W.
 WASHINGTON, D.C. 20005-3701

ACRS CONSULTANT:

STEPHEN SCHULTZ

DESIGNATED FEDERAL OFFICIAL:

CHRISTOPHER BROWN

DEREK WIDMAYER

ALSO PRESENT:

STEVEN LYNCH, NRR

TRACY RADEL, SHINE Medical Technologies

JIM COSTEDIO, SHINE Medical Technologies

JON DELVENTHAL, SHINE Medical Technologies

CATHERINE KOLB, SHINE Medical Technologies

JON OLVERA, SHINE Medical Technologies

JEFFREY BARTELME, SHINE Medical Technologies

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

C-O-N-T-E-N-T-S

	<u>PAGE</u>
Opening Remarks and Objectives	
by Ronald Ballinger, ACRS Chairman	6
Staff Opening Remarks	
by Steven Lynch, NRR	9
Overview of SHINE Medical Isotope Production Facility, opening remarks	
by Jim Costedio	10
Overview of SHINE Medical Isotope Production Facility	
by Tracy Radel	11
Public Comments	19
Break for closed session	19
Approach to Review of SHINE Operating License Application	
By Steven Lynch, NRR	20
Closing Remarks	
By Ronald Ballinger, ACRS Chairman	62

P R O C E E D I N G S

(9:30 a.m.)

CHAIRMAN BALLINGER: This meeting will now come to order. This is a meeting of the SHINE, of the Advisory Committee on Reactor Safeguards, the SHINE NPUF Subcommittee.

I'm Ron Ballinger, Chairman of the SHINE Subcommittee. We have a quorum, so there's no need to call the attendance, I don't think. Christopher Brown and Derek Widmayer are the Designated Federal Officials for this meeting. I think the Court Reporter's on, yes.

The purpose of today's meeting is for the subcommittee to receive a briefing from SHINE Medical Technologies, LLC, which will consist of an overview of SHINE medical isotope production of the facility.

Also, we'll hear from the staff on their approach to review the SHINE operating license application.

The ACRS was established by statute and discovered by the Federal Advisory Committee Act, FACA.

The NRC implements FACA in accordance with its regulations found in Title 10 of the Code of Federal Regulations, Part 7.

The committee can only speak through its published letter reports. We hold meetings to gather

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

(202) 234-4433

(202) 234-4433

1 information and perform preparatory work that will
2 support our deliberations at a full committee meeting.

3 The rules for participation in all ACRS
4 meetings were announced in the Federal Register on June
5 13th, 2019. The ACRS section of the U.S. NRC public
6 website provides our charter, bylaws, agendas, letter
7 reports, and full transcripts of all full and
8 subcommittee meetings, including slides presented
9 there.

10 The meeting agenda for this meeting is
11 posted there. Portions of this meeting will be closed
12 to protect proprietary information pursuant to 5
13 U.S.C. 552b(c)(4).

14 For the open part of this meeting we have
15 -- we'll also have set aside five minutes for comments
16 from members of the public contending or listening to
17 this meeting. We've had no request for making a
18 statement to the subcommittee.

19 A transcript of the meeting is being kept
20 and will be available on our website for the open portion
21 of the meeting. Therefore, we've requested
22 participants in this meeting to first identify
23 themselves and speak with sufficient clarity and volume
24 so that they can be readily heard.

25 Please pause from time to time to allow

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 members to ask questions. Also, for presenters,
2 because of the video nature of this thing, this meeting,
3 please sometimes let us know what slide number you're
4 on.

5 We have a bridge-line established for the
6 public to listen in to the meeting. To minimize
7 disturbance, the public line will be kept in a listening
8 mode only. Public line will be terminated during the
9 closed session.

10 Okay, okay. Note that we have scheduled
11 the next subcommittee meeting for January 13th, 2021.

12 Per our many discussions, we are asking for SERs that
13 have been completed before the December 13th due date.

14 Also, I'll probably say this in closing
15 remarks, but in case I forget, we will have a meeting
16 to discuss the review format for SHINE in December at
17 our P&P meeting.

18 So it's very important that by that time
19 we have available feedback from members related to the
20 format that we might be -- that we'll be agreeing to.

21 So having said that, I think we need to
22 turn to, I guess, Steve Lynch, who'll give some staff
23 opening remarks. Steve, are you there?

24 MR. LYNCH: Yes, I am here. Thank you.

25 So for everyone, my name is Steve Lynch.

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 I'm a Senior Project Manager in the Non-Power
2 Production and Utilization Facility licensing branch
3 in the office of Nuclear Reactor Regulation at the NRC.

4 I am the lead project manager for the review of the
5 SHINE operating license application.

6 I appreciate the opportunity that the
7 members are providing both SHINE and the NRC staff this
8 morning to provide an introduction to this review.
9 It is important not only to our agency, but also to
10 providing medical care to citizens of the United States
11 and around the world for the production of molybdenum-99
12 and other radioisotopes.

13 Our goal for this meeting this morning is
14 to familiarize ACRS with the NRC staff's approach to
15 reviewing the SHINE operating license application,
16 recognizing some of the unique technical and licensing
17 considerations associated, a subcritical operating
18 assembly, and production facility to be licensed under
19 10 C.F.R. Part 50.

20 So we hope that coming out of this meeting
21 we can further the conversation on the strategy for
22 engaging in additional technical subcommittee meetings
23 to --and make sure that we are able to get the ACRS
24 members the information that they need in order to
25 conduct their independent review of the application,

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 and the staff's safety evaluation.

2 So thank you for your time today and I'll
3 look forward to presenting later this morning.

4 CHAIRMAN BALLINGER: Thanks, Steve. So
5 now, I guess we turn it over to the SHINE folks. And,
6 Tracy, are you on?

7 MR. COSTEDIO: Yes. Good morning, this
8 is Jim Costedio. I'm the --

9 CHAIRMAN BALLINGER: Whoops, you're not
10 Tracy. Sorry.

11 MR. COSTEDIO: No, I'm not. I wanted to
12 open. I'm the vice president of regulatory affairs
13 and quality for SHINE. And we want to thank the ACRS
14 subcommittee members for hosting us virtually today.
15 We're very excited to be here. It's been a long time
16 since we last met, I think October of 2015. So we have
17 made significant progress as to the construction permit
18 phase.

19 Today we're going to discuss design
20 refinements that have resulted in some changes to the
21 facility. All these changes were made to improve
22 safety, constructability, and operation of the
23 facility.

24 We're also going to discuss our
25 construction status, technological approach, safety

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 philosophy, and give a process overview.

2 So we look forward to, and we'll embrace
3 the feedback from the ACRS subcommittee today. So we
4 have a lot to cover. Thanks again, and I'll turn it
5 over to Tracy Radel, our VP of engineering.

6 MS. RADEL: Thanks, Jim. I echo Jim's
7 remarks in that we are very excited to present the
8 overview today of the SHINE design, and we look forward
9 to the questions, comments, and conversation that will
10 come out of this.

11 So let's get started. The stuff we'll
12 cover in the open session today includes the site plan,
13 the status of our construction process overview,
14 technological approach, and our safety philosophy.

15 SHINE's site is located in Janesville,
16 Wisconsin. You can see it here in this overhead view
17 outlined in red. As we zoom in you can see the site
18 plan shows where the production facility is relative
19 to the different support and outbuildings for the
20 facility.

21 Here's a rendering of the site. So you
22 can see what we expect it to look like, or about what
23 we expect it to look like when the construction is
24 finished.

25 We're currently undergoing construction

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 on the main production facility, the building at the
2 center there. The construction status, here's some
3 images of recent construction status. So rebar,
4 there's a significant amount of rebar in the facility.

5 You can see there this is the rebar for
6 the second lift on the east wall. You can also see
7 it in the picture here at the bottom. Here's a overhead
8 view from the crane. You can see the layout of the
9 facility, the different subgrade faults here.

10 There's a significant number of embedded
11 items. Conduits, penetrations, pipe sleeves, some of
12 those shown here. And then in the upper right corner
13 here is a view down the irradiation unit cells prior
14 to the dividing walls being placed.

15 MEMBER BLEY: Tracy?

16 MS. RADEL: Yes?

17 MEMBER BLEY: This is Dennis Bley. One
18 question on this slide and then I'd like to go back
19 two. In seeing the conduit here, I don't remember,
20 are all your cables going to be in conduit? Or some
21 in cable trays?

22 MS. RADEL: There are cable trays as well
23 as conduit.

24 MEMBER BLEY: Okay.

25 MS. RADEL: Basically.

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 MEMBER BLEY: And back two slides.

2 MS. RADEL: Okay.

3 MEMBER BLEY: I'm sorry, one more. I
4 didn't remember. I remembered that you were very close
5 to this small airport. I didn't remember that you were
6 kind of almost lined up with that southwest to northeast
7 runway. That's always been your site thought, right?
8 In that same location?

9 MS. RADEL: Yes. It's the same site as
10 we had with the construction permit.

11 MEMBER BLEY: Okay. Thank you.

12 MS. RADEL: Okay. And moving on to the
13 process overview. The process begins with the
14 preparation of target solution. We take uranium oxide
15 and dissolve in sulfuric acid and peroxide, adjust for
16 pH and uranium concentration. That's the put into the
17 process into a hold tank.

18 There are eight hold tanks. One for each
19 of the irradiation units. It is then loaded into the
20 irradiation unit using a 1/M approach. Once the
21 solution has been filled to the proper level, which
22 is nominally 5% by volume below predicted critical,
23 the irradiation unit is isolated, and irradiation
24 begins.

25 Irradiation is for approximately five and

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 a half days. And then following the five and a half
2 days of irradiation, it would be gravity drained to
3 a favorable geometry. Dump tank at the base of the
4 subcritical assembly where it would be allowed to cool
5 and a short decay period for short-lived fission
6 products.

7 Following that, it is transferred over to
8 the supercell where the molybdenum is extracted, and
9 the target solution would then flow back to the target
10 solution hold tanks.

11 The molybdenum would go through the
12 different processes within the supercell, which include
13 purification, QC checks, and then packaging before
14 being shipped out.

15 In the process of extraction and
16 purification, there are liquid wastes generated. That
17 liquid waste would be immobilized through the
18 solidification process.

19 Any questions on that?

20 MEMBER PETTI: Yes, I had a question on
21 the tritium waste. The tritium is going to permeate
22 and get into your atmosphere, and I assume you're going
23 to be cleaning up the atmosphere. And what's the
24 ultimate path for the tritium?

25 MS. RADEL: So the tritium purification

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 system, we capture that tritium and then purify it using
2 that TCAP system. There's additional slides in the
3 closed session and that process.

4 And to be clear, the tritium system would
5 be within the tritium target chamber of the --at the
6 center of the subcritical assembly. It wouldn't be
7 in with the uranyl sulfate solution process flow here.

8 So there's quite a few more details in the closed
9 session about how the tritium purification system
10 works.

11 MEMBER PETTI: Okay, thanks. I'll wait.

12 MS. RADEL: Okay.

13 MEMBER KIRCHNER: Tracy, this Walt
14 Kirchner. And then after the target solution, that's
15 LEU, right?

16 MS. RADEL: Yes. LEU.

17 MEMBER KIRCHNER: Thank you.

18 MEMBER PETTI: And so just a question,
19 compared to the traditional way to make moly-99 with
20 ATU, is this high-specific activity or low-specific
21 activity moly-99 in terms of the separation? Or is
22 it like medium?

23 MS. RADEL: It's high specific activity.

24 MEMBER PETTI: It still is? Okay.

25 MS. RADEL: Yes.

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 MEMBER PETTI: Thanks.

2 MS. RADEL: And moving on to the
3 technological approach. So one key item is that these
4 are small systems; so the license limit power of each
5 of the irradiation units is 125 kilowatts. This is
6 hundreds of times less power than isotope production
7 reactors currently being used.

8 This leads to a much lower source term,
9 which helps ensure the safety of the public and
10 workforce. It also leads to lower decay heat. We're
11 at less than a kilowatt within five hours.

12 And the solution is passively cooled by
13 the light water pool following irradiation. It also
14 minimized the waste generated in the isotope production
15 because the majority of fissions that are occurring
16 within the system are occurring to produce recoverable
17 moly.

18 So in the current system, the reactors have
19 a significant amount of fission occurring within the
20 fuel that is not directly going to generating moly for
21 isotope production.

22 We use a low-enriched uranium reusable
23 target. The ability to reuse the target efficiently
24 greatly reduces waste.

25 The use of a uranium target means that it's

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 compatible with the current supply chain producing that
2 high-specific activity moly that the industry is used
3 to. And the use of low-enriched uranium eliminates
4 the need for highly enriched uranium.

5 It's driven by a low-energy electrostatic
6 accelerator. This means that when the accelerator is
7 turned off that the fission essentially terminates
8 shortly after. And this a key design feature of the
9 system.

10 The multiple units, multiple irradiation
11 units, and multiple processing trains provide
12 operational flexibility and scalability. So we have
13 eight individual irradiation units, and then we have
14 three independent processing lines.

15 And each of the eight irradiation units
16 can be processed through multiple processing lines.

17 MEMBER BLEY: Tracy, maybe you're going
18 to talk about this in the closed session, I'm not sure,
19 but last time around the way designed this you were
20 running very close to critical. Have you changed your
21 plans for operating regime? Or is going to be about
22 the same as we saw before?

23 MS. RADEL: It's about the same as before.
24 So the 5% by volume below critical, and there is more
25 on that in closed session.

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 MEMBER BLEY: Thank you.

2 MS. RADEL: Yes. Part of the safety
3 philosophy, the systems are at low pressure slightly
4 so the atmospheric low temperature and have a low decay
5 heat. And this means that there's minimal stored
6 energy there to drive any type of release if it were
7 to occur.

8 The independence of the eight irradiation
9 units limits common cause failures, it limits the source
10 terminates available. The units do not require any
11 operator actions to mitigate the consequences of an
12 accident.

13 And in the event of an on-site condition,
14 the TSV reactivity protection system would initiate
15 a trip. That trip would open two completely
16 independent safety related TSV dump valves, and the
17 target solution would gravity drain to the TSV dump
18 tank, which is safe for all uranium concentrations.

19 The hydrogen concentration is maintained
20 below the lower flammability limit by the off-gas
21 system. Following the battery run time, the entire
22 plant is passively safe. So the target solution was
23 cooled by the pool it's sitting in. And the pool
24 temperature would not rise more than 13 degrees over
25 90 days without any active cooling.

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 The nitrogen purge system provides
2 hydrogen control. It provides a sweep gas through the
3 system to purge the hydrogen.

4 MEMBER PETTI: Just a question on the
5 accelerators and the assumptions of your design.
6 There's a certain level of fusion that occurs, is there
7 a margin in terms of what if you get better fusion than
8 you think and so you end up with more neutrons and,
9 you know, going into the uranium. Is there a margin
10 there?

11 MS. RADEL: Yes, so the power is monitored
12 through the detectors, and they would catch any kind
13 of increase in production of the drivers, which would
14 drive, you know, power up within the subcritical
15 assembly.

16 There's not a mechanism that would lead
17 to drastically increased production by the neutron
18 drivers beyond what they've been testing or show to
19 be capable of. And we can talk more in details of that
20 in the closed session.

21 MEMBER PETTI: Okay.

22 MR. RADEL: Okay. Any other questions?
23 This is the last slide for open session.

24 CHAIRMAN BALLINGER: No questions? We
25 have made a potentially fatal error in that we're ahead

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 of schedule. I think at this point we need to make
2 sure the public line. I'm assuming it is. So I think
3 it is, yes, yes.

4 So are there any members of the public that
5 would like to make a comment?

6 MALE PARTICIPANT: The line is open for
7 comment.

8 CHAIRMAN BALLINGER: Thank you. If so,
9 please state your name and make your comment.

10 I'm hearing none. I think we can close
11 the public line.

12 We need to now transfer to the closed
13 session. Let me go offline -- transfer to the closed
14 session. So we need to leave this session and then
15 rejoin in the closed session. So we should take about
16 a ten-minute break. It's 9:52 so at just a little bit
17 after 10, say 10:05, to round things up.

18 We'll rejoin in the closed session. So unless
19 there are other member comments, we'll now leave this
20 session, and we'll see you in the closed session.

21 (Whereupon, the above-entitled matter went
22 off the record at 9:52 a.m. and resumed at 11:55 a.m.)

23 CHAIRMAN BALLINGER: Okay. It's 11:55.
24 We're back in session and I think Steve Lynch, you're
25 up.

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 MR. LYNCH: Yes. Thank you very much.
2 Thankfully my Teams just cooperated, and I am back
3 online. Just confirm for me when you can see my
4 presentation slides that I'm sharing.

5 CHAIRMAN BALLINGER: I could see your
6 slides but it's not full screen.

7 MR. LYNCH: Okay. Let's do that right
8 now. Okay. Now I can take of this.

9 CHAIRMAN BALLINGER: Looking good.

10 MR. LYNCH: Okay. Thank you everyone for
11 your time this morning and afternoon. I will try to
12 make sure I pay attention to the time, but if we need
13 to speed up feel free to let me know and we can adjust
14 the pace.

15 To compliment SHINE's presentation
16 regarding the overview of their technology, what I'd
17 like to present today as a first step is our engagement
18 with the ACRS members on the SHINE Medical Technologies
19 operating license application review is to provide some
20 background and also the test and methodology with the
21 NRC staff needed to review the SHINE operating license
22 application.

23 And hopefully what we can do coming out
24 of this meeting is continue our conversation on how
25 to best approach the technical subcommittee meetings

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 that are to follow this licensing meeting that we have
2 having so that we can one, make sure that we're providing
3 the information that is most useful to the ACRS members,
4 and also make sure that we are streamlining our process
5 to the extent that we are presenting information in
6 a way that is focusing on what's most safety significant
7 for this application, and providing appropriate context
8 for the discussions that we have.

9 So the first couple slides I'm going to
10 go through some background on our NRC staff involvement
11 in these reviews, some of the drivers that come from
12 applicable statutes, coordination with other federal
13 agencies, and also drivers that we have from external
14 to external to the government.

15 So when it comes to medical radioisotopes,
16 and in particular, the production of molybdenum-99 that
17 SHINE is proposing to produce, there is a significant
18 effort from the international community, and in line
19 with U.S. policy, to establish a domestically available
20 and reliable supply of this medical radioisotope
21 without using highly enriched uranium.

22 SHINE discussed earlier this morning they
23 are using an LEU solution in order to produce
24 molybdenum-99. As you may know, 6% of the fission
25 products of U-235 are molybdenum-99. And when you have

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

(202) 234-4433

(202) 234-4433

1 those pure molybdenum-99 fission products, you do end
2 up with high-specific activity technetium-99
3 metastable because you don't have other molybdenum
4 isotopes that could reduce the specific activity that
5 then is provided as the radiopharmaceutical for
6 diagnostic or therapeutic purposes.

7 As far as the NRC is concerned, we do look
8 at initial license applications and license amendment
9 requests for a variety of different types of licensing
10 actions that involving manufacturing of targets for
11 irradiation, the actual technologies that are used for
12 irradiation, and the processing of those targets once
13 they've been irradiated.

14 For the purposes of the office of Nuclear
15 Reactor Regularization, our focus is primarily on those
16 utilization and production facilities that are covered
17 under 10 C.F.R. Part 50, which is our framework that
18 we use primarily for reviewing nuclear power reactor
19 and non-power reactor facilities.

20 In terms of what our drivers are outside
21 of our regulations and the applications that come to
22 us, we do have coordination with other federal agencies
23 for reviews related to molybdenum-99. In particular,
24 there is the American Medical Isotopes Production Act
25 that does provide the coordination between the NRC's

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 staff and the National Nuclear Security Administration.

2 There are two key provisions of this act
3 that are applicable to the NRC. One of those is on
4 coordination of the National Environmental Policy Act
5 of use, or environmental disuse.

6 Basically, the provision there is for those
7 actions where both the NSSA and the NRC have federal
8 jurisdiction should we need to coordinate on those NEPA
9 reviews. So we are preparing a joint supplemental
10 environmental impact statement to support the review
11 of the operating license application with NSSA.

12 And then the other piece of this is a
13 uranium lease and take-back program. The act provided
14 that DOE NSSA establish this uranium lease and take-back
15 program in particular so that if there is waste that
16 does not have a commercial disposition pathway that
17 the Department of Energy, through an agreement with
18 an applicant, would be responsible for disposing of
19 that waste.

20 And that program is established and
21 available to all applicants through SHINE. Also, there
22 is coordination with the Department of Homeland
23 Security, and this has to do with site vulnerability
24 assessments that are performed for any new utilization
25 facility constructed in the United States.

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 This vulnerability assessment was
2 performed at the construction permit stage of the SHINE
3 review, and the results of that were taken into
4 consideration by both the NRC staff and the applicant
5 in the review of the application and preparation of
6 the application.

7 And then the other act that I would like
8 to highlight here that is applicable to the work that
9 we are doing is the Nuclear Energy Innovation and
10 Modernization Act.

11 Among the many provisions of this act, one
12 of the items that is applicable to our review of the
13 SHINE operating license application is the
14 establishment of review periods, in particular, from
15 an initial licensing application setting a generic
16 review schedule of three years is provided for the NRC
17 staff to establish.

18 As I go on, I do want to just from an
19 administrative point of view, I am hearing some pop-ups
20 and potential comments coming up. Unsure if they're
21 being directed to me or not. I just want to say that
22 while I've got my presentation in full screen mode,
23 I can't see any text messages that may be sent via Teams.

24 So if someone, particularly the ACRS members, if you
25 have something you'd like for me to address, please

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 speak up.

2 CHAIRMAN BALLINGER: This is Ron. I don't
3 think we use that method.

4 MR. LYNCH: Okay.

5 CHAIRMAN BALLINGER: So you'll hear
6 voices.

7 MR. LYNCH: Okay. No problem. I just
8 wanted to make sure that I'm not missing anything
9 because I can't see it.

10 Okay. Now, to get back into a little bit
11 more of the policy work that the NRC staff has engaged
12 in to prepare for the review of non-power production
13 or utilization facility reviews and the SHINE review,
14 there's a couple rulemakings that I do want to highlight
15 that are of particular relevance and importance to the
16 work that we're doing.

17 One of these is the non-power production
18 or utilization facility, or NPUF, license renewal final
19 rule that was submitted to the commission for
20 consideration in June of 2019.

21 While the focus of this rule was looking
22 at eliminating license renewal terms for certain NPUF
23 facilities, one of the other provisions of this rule
24 that will have a direct impact on our licensing of
25 facilities like SHINE is the establishment of an

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

(202) 234-4433

(202) 234-4433

1 accident dose criterion, which does not currently exist
2 in our regulations for a facility like SHINE.

3 So what that would do is establish an
4 accident dose criterion of one rem at the site boundary
5 for facilities like SHINE.

6 Currently, in absence of having a
7 regulatory requirement for accident dose criterion for
8 non-power production and utilization facilities, the
9 NRC staff has conservatively accepted proposals from
10 currently licensed non-power reactors 5 and medical
11 radioisotope facilities, like SHINE, to previously use
12 100 millirem as their accident dose criteria, which
13 is consistent with the normal annual release limits
14 in 10 C.F.R. Part 20.

15 So expanding to the one rem dose limit is
16 consist with the EPA PAGs. And I believe through the
17 regulatory audit we had with SHINE on their accident
18 analysis, SHINE is planning on adopting that accident
19 dose criterion of one rem for their facility.

20 And then the other rulemaking that is
21 important to the work that we're doing with SHINE that
22 kind of guides the regulatory review that we are doing
23 was the definition of utilization facility direct final
24 rule that was published in the Federal Register in
25 October of 2014.

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 The significance of this rulemaking was
2 expanding the definition of utilization facility in
3 10 C.F.R 50.2 to include, by docket, a SHINE accelerator
4 driven subcritical operating assemblies.

5 So this was a rule of particular
6 applicability, meaning that it was limited to a single
7 entity. So in order to ensure that we did not have
8 unintended consequences by impacting other subcritical
9 facilities, this rulemaking was limited to just the
10 SHINE technology.

11 And the practical implication of this
12 rulemaking is providing that the SHINE subcritical
13 operating assemblies would be licensed as utilization
14 facilities. So they would follow a similar licensing
15 path to non-power reactors that are licensed by the
16 NRC.

17 Now I touched on this briefly in one of
18 my earlier slides, but I did want to highlight the scope
19 of technologies that are covered under radioisotope
20 production processes that the NRC looks at. And this
21 really breaks down into four main categories.

22 We've got target manufacturing, target
23 irradiation, target processing, and then the medical
24 use of byproduct material. For the SHINE application,
25 what we are focused on is the target irradiation using

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 subcritical operating assemblies, and then the target
2 processing that utilizes SHINE's hot cell facility to
3 process the irradiated low-enriched uranium solution
4 to extract the molybdenum-99.

5 The target manufacturing we have seen for
6 other applications for the manufacturing of solid LEU
7 targets that would be placed in reactors for other
8 facilities or irradiation. And then the medical use
9 of byproduct material really gets down to the generators
10 that actually are doing the extraction of the
11 technetium-99m from the molybdenum-99, which is not
12 part of the SHINE proposal.

13 And when we're -- you know, one of the
14 things that drove our rulemaking to classify SHINE's
15 subcritical operating assemblies as utilization
16 facilities really came down to what were the safety
17 considerations for that facility.

18 When we were looking at this there was the
19 initial where the question came up because in order
20 to be a utilization facility under the NRC's traditional
21 regulatory framework, a facility would need to be a
22 nuclear reactor, meaning that it is capable of a
23 self-sustaining chain reaction or having that
24 criticality.

25 Being a subcritical facility, SHINE did

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 not meet that definition of a nuclear reactor.
2 However, due to the limited margin or subcriticality
3 that SHINE has, there were many safety considerations
4 that made more sense to look at the SHINE subcritical
5 operating assembly more similarly to how we would
6 evaluate an aqueous simultaneous reactor, including
7 removal of fission heat, aheat generation, generation
8 of fission gasses, and also looking at the potential
9 accident scenarios.

10 That being said, with the SHINE hot cell
11 facility there are other technical considerations that
12 fall outside of the normal scope of what we would look
13 at for a reactor technology.

14 And for SHINE in particular, this has to
15 do with some of the criticality considerations for the
16 hot cell facility. Making sure that there is an
17 approved margin of subcriticality in the hot cell
18 facility, and also making sure that SHINE's criticality
19 safety program is applied consistently throughout the
20 facility in all of those areas except for the target
21 solution vessel where the goal is to have that minimum
22 margin of subcriticality.

23 And then, also the importance is looking
24 at some of the chemical hazards associated with license
25 material that are present in the facility due to the

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 processing of the irradiated targets that we've shown.

2 So to kind of bring all of this together,
3 our organization, the Division of Advanced Reactors
4 of Non-Power Production of Utilization Facilities, does
5 have the primary responsibility for leading the project
6 management and reviews of non-power production of
7 utilization facilities, including the medical
8 radioisotope facilities. And this includes looking
9 at non-power reactor technologies, subcritical
10 operating assemblies, and production facilities.

11 The SHINE facility is going to be licensed
12 as a commercial facility under Section 103 of the Atomic
13 Energy Act. And this does contribute some slight
14 differences in how we look at their facility versus
15 how we would review a research or test reactor.

16 And mainly this comes down to the
17 implementation of the minimum regulation provision of
18 the Atomic Energy Act that is afforded to research and
19 test reactors licensed under Section 104c.

20 So as a commercial facility, SHINE does
21 not have that minimum regulation provision applicable
22 to them. That being said, we are tailoring our review
23 based on the safety significance of the facility to
24 ensure that our resources and reviews are focused on
25 those safety related structures, systems, and

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 components that are necessary to protect the public
2 health and safety.

3 So given the different types of
4 technologies that we're looking at with SHINE, we are
5 relying on the technical expertise from organizations
6 throughout the NRC outside of NRR.

7 And, in particular, we are looking to the
8 office of Nuclear Security and Incident Response to
9 help with our reviews of emergency planning and physical
10 security.

11 We also are looking to our office of Nuclear
12 and Material Safety and Safeguards to help with looking
13 at the material component accounting program, support
14 and accident analysis review, chemical safety, and
15 criticality safety, which are expertise areas that we
16 do not have in NRR to complete this review.

17 Now a little bit of background on the SHINE
18 application itself. Previously we did receive a
19 two-part instruction permit application in 2013 for
20 the SHINE facility that consisted primarily of an
21 environmental report and preliminary report.

22 As you heard from SHINE, the basic process
23 involves irradiating and low-enriched uranium target
24 solution in its irradiation facility consisting of
25 eight irradiation units, and then processing that

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

(202) 234-4433

(202) 234-4433

1 irradiated target solution in the radioisotope
2 production facility consisting of the hot cells.

3 Following our review of this application,
4 a construction permit was issued in February of 2016
5 and SHINE commenced construction of its facility in
6 September of 2019 in Janesville, Wisconsin.

7 I do want to just clarify on this date for
8 commencing construction. This is what the NRC staff
9 considers construction under our definitions in 10
10 C.F.R 50.10. My understanding is that SHINE did have
11 other site preparation work that had to be done prior
12 to that September 3rd date.

13 Now this touches a little bit on the items
14 that were highlighted in the ACRS member letter I follow
15 that supported issuance of the construction permit and
16 looking at what was covered in that appendix A of the
17 staff safety evaluation report, which covered items
18 that would need follow-up past the issuance of the
19 construction permit.

20 There were several items contained in that
21 appendix. Among those include these periodic reports
22 on permit conditions were addressed. We also had
23 technical areas where SHINE had made regulatory
24 commitments to provide information in the operating
25 license application for the NRC staff review to make

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

(202) 234-4433

(202) 234-4433

1 an ultimate safety finding.

2 So before I get into the particulars of
3 these permit conditions, what I'll highlight when it
4 comes to how the staff is conducting its review of this
5 Part 50 application, at the construction permit stage,
6 the NRC staff did not make any ultimate safety findings
7 that were final.

8 And because of the nature of the SHINE
9 design that was going to continue to evolve as it went
10 from a preliminary design to a final design. And I
11 believe that's highlighted with the design changes that
12 SHINE presented at the beginning of today's meeting.

13 So what this means is while the NRC staff
14 conducted a review of all of the available information
15 at the construction permit stage as described in that
16 appendix A, and in the regulations in 10 C.F.R. 50.35,
17 there is an expectation that information that had not
18 previously been reviewed or considered would be made
19 available to the NRC staff in order to make its safety
20 findings and ultimately issue an operating license
21 application.

22 So because the --

23 RECORDING: Mute on.

24 MR. LYNCH: I'm sorry, one sec. Okay.

25 That was not my mute, so I am still here. My apologies.

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 Let me get back to full screen. I just wanted to make
2 sure that I was not inadvertently muted.

3 So my apologies. So essentially what I
4 would like to highlight here is going from the
5 construction permit review to the operating license
6 application review, the NRC staff is not so much
7 conducting a delta review looking at those differences,
8 so much as we are potentially taking a fresh review
9 of the application.

10 So in all areas that we looked at during
11 the construction permit application review, we are
12 looking at again, based on the updated and complete
13 design information provided in the SHINE final safety
14 analysis report.

15 That being said, the NRC staff is informing
16 its review of this final information by looking back
17 to the items highlighted in appendix A for those areas
18 where SHINE had made commitments to providing updated
19 -- and to the extent that design changes have made
20 certain commitments no longer applicable and necessary,
21 the NRC staff will make note of that as part of our
22 ultimate evaluation findings.

23 And, you know, our intent is also as we
24 prepare our safety evaluation report, input to address
25 these areas in appendix A to make sure that, yes, the

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

(202) 234-4433

(202) 234-4433

1 NRC staff did make a standalone review of the FSAR
2 information to the extent that they were relevant and
3 valid.

4 And the commitments made by SHINE at the
5 construction permit stage that are also applicable and
6 necessary for us to make our necessary evaluation
7 findings based on our standard review plan and the
8 regulatory findings in 10 C.F.R., we will make sure
9 that all of that is addressed and presented to the ACRS
10 members as we go through our technical presentations.

11 With respect to these particular periodic
12 reports, recognizing that SHINE had a fair amount of
13 development work to go when the construction permit
14 was issued in the areas of its criticality accident
15 alarm system, nuclear criticality safety evaluations,
16 and additional shielding design application, the NRC
17 staff did have these conditions on the permit for SHINE
18 to provide reports to us that would provide updates
19 on how they were developing the information.

20 The primary goal in having this information
21 was to support construction inspection activities
22 should they have to be done prior to the submission
23 of the operating license application, and that would
24 contain the complete technical -- to make sure that
25 our inspectors would have all of the information they

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 needed in order to conduct their inspections.

2 Now based on how the timing of all of this
3 worked out, while we've had these periodic reports
4 submitted by SHINE, SHINE submitted its operating
5 license application in July of 2019, and our first
6 construction inspection activities began in December
7 of 2019 following SHINE's commencement of construction
8 in September of 2019.

9 So the inspection information that we are
10 using is based on the FSAR and supporting materials
11 that SHINE provides to NRC staff in its electronic
12 reading as necessary to support specific inspection
13 activities.

14 So while SHINE provided this information,
15 the current information that we are using support our
16 review and inspection activities is based on the end
17 test for that.

18 So with this, I think I can go through the
19 next few slides fairly quickly as we've covered most
20 of this already. The main point here that I want to
21 emphasize is that the SHINE irradiation facility, which
22 consists of the eight subcritical irradiation units
23 is going to be licensed and reviewed against the
24 requirements in 10 C.F.R. Part 50, which mostly mirror
25 those requirements used to evaluate applications for

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

(202) 234-4433

(202) 234-4433

1 non-power reactors.

2 And then for the radioisotope production
3 facility, this is also evaluated under the NRC staff
4 regulations and guidance under Part 50 for a production
5 facility.

6 As you may be familiar, there are three
7 different types of production facilities described in
8 the NRC's regulations. This includes those production
9 reactors used for the production of special nuclear
10 material, like the Hanford reactor, new processing
11 facility, like the West Valley facility, and then the
12 third type of production facility is for those
13 facilities used for the separation of byproduct
14 material from irradiated special nuclear material.

15 And that's what all of the medical
16 radioisotope facilities have proposed that are using
17 low-enriched uranium and having separation processes.

18 Now the important distinction here, and
19 when we're determining what the appropriate licensing
20 process is to apply to these facilities, we are looking
21 at what is the batch size, so how much special nuclear
22 material is going to be processed at one time.

23 In our regulations there is a threshold
24 drawn at 100 grams. So if a facility is processing
25 greater than 100 grams of special nuclear material at

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 one time, that is what pushes them into the Part 50
2 requirement for a production facility.

3 If a facility were to stay below that 100
4 ram threshold, they would be licensed under 10 C.F.R.
5 Part 70 for similar to existing fuel cycle facilities.

6 That being said, while the SHINE production
7 facility is being licensed under 10 C.F.R Part 50, as
8 I mentioned earlier, we are relying on technical staff
9 from our office of NMSS to support us in our review
10 of certain accident sequences, criticality safety, and
11 chemical safety to the extent that there are technical
12 similarities between the production facility and fuel
13 cycle facilities.

14 So in addition to the Part 50 license that
15 SHINE has requested, there would be provisions under
16 this license ensuring that SHINE is meeting applicable
17 proximity requirements for the possession and use of
18 special nuclear material, and for the possession and
19 use of source material under Part 70 and Part 40,
20 respectively.

21 Now I'll transition to a little bit more
22 talking about the specifics of the NRC staff review
23 of the operating license application that was submitted
24 by SHINE back in July of 2019.

25 So following that submission of the

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 application back in July, the NRC staff performed a
2 60-day acceptance review of the application and
3 accepted the application for review in October of 2019.

4 Based on this accepted review, the NRC
5 staff did highlight certain technical areas that were
6 going to require focused attention and engagement
7 between the NRC staff and SHINE in order to make sure
8 that we've reached a technical and licensing
9 resolution.

10 The two main topics identified were
11 instrumentation and control systems, and the accident
12 analysis and methodology. The reasoning for
13 highlighting these areas, we recognize that for SHINE's
14 instrumentation and control systems they are utilizing
15 the Rock Creek platform that NuScale has used for its
16 I&C systems.

17 And in particular, our staff wants to make
18 sure that from the safety evaluation prepared for the
19 NuScale system that appropriate consideration has been
20 given to the 65 application specific items in our review
21 of the application, and making sure that we are
22 consistent in our review methodologies of the SHINE
23 I&C systems and of recent digital upgrades we've had
24 for research reactors.

25 MEMBER BROWN: Can I ask a question, Steve?

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 MR. LYNCH: Sure. Absolutely.

2 MEMBER BROWN: When you talk about
3 utilizing the NuScale systems, does that mean -- and
4 you talked about the Rock Creek, the most reasonable
5 would be -- I may be on the wrong branch with this,
6 but their reactor protection system and their ESFAS
7 system, whichever one, however we want to call it here,
8 utilize field programmable gate arrays as opposed to
9 microprocessors in the their processing. Is that what
10 you're talking about? Because we've seen nothing
11 relative to what they look like now.

12 MR. LYNCH: Sure. So at a high level, what
13 I will say SHINE does have an ESFAS system in the --

14 RECORDING: Mute on.

15 MR. LYNCH: In the Rock Creek platform that
16 has been customized for SHINE. With respect to the
17 use of the microbe processors, I think I would refer
18 to SHINE to answer what they are specifically using
19 in that.

20 But it is a -- but what I will say is that
21 it isn't an exact replica of the NuScale platform.
22 It has been customized for SHINE.

23 MEMBER BROWN: Well, customization is
24 fine. I understand there's a big difference between
25 an operating plant and this facility set up. And if

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 that difference was, you know, evident in our earlier
2 review, I was just wondering if when you say it was
3 consistent, the FPGA approach that they used is not
4 a software-based driven system.

5 It was almost like hard-wired stuff once
6 you program the FPGAs. So that's all I was interested
7 in when you were talking about the details. Because
8 we didn't get that detail before.

9 MS. RADEL: Yes. So this is Tracy Radel
10 with SHINE again. We are using the HIPS platform highly
11 integrated protection --

12 MEMBER BROWN: Okay.

13 MS. RADEL: --system from Rock Creek and
14 it is using those field programable gate arrays, the
15 FPGAs.

16 MEMBER BROWN: Okay. Excellent. That's
17 just what -- I wanted to make sure I -- I didn't refer
18 to it as Rock Creek. I always thought of it as HIPS.
19 So you said the magic words.

20 MS. RADEL: Yes.

21 MEMBER BROWN: Okay. Thank you very much.

22 MR. LYNCH: Thank you. And then the other
23 focus area for the NRC staff has been the accident
24 analysis performed by SHINE.

25 We've had some successful audits.

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 Actually, both of these technical areas that has
2 furthered our review, in particular, with the accident
3 analysis methodologies.

4 One of the outcomes of our recent audit
5 with SHINE that I began in August of this year and
6 concluded a few weeks ago in October was reevaluating
7 how SHINE was performing its accident analysis to make
8 sure that a complete set of design basis accidents were
9 presented in the application, and also to ensure that
10 we had a mutual understanding of how SHINE was using
11 its SHINE safety analysis that is an undocketed report
12 that SHINE discussed that covered additional accident
13 sequences and controls that had been identified for
14 different accident categories, and making sure that
15 we had connection between the SSA, SHINE's design basis
16 accidents, and then ultimately what is being treated
17 as a founding accident scenarios against a one rem
18 criteria.

19 So this here, we do have a set up request
20 for additional information on the accident analysis
21 that are prepared. They're in concurrence right now
22 and ready to be issued this week. And we are expecting
23 to have responses for requests for additional
24 information, and an updated safety, final safety
25 analysis report on this information submitted in about

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 30 days.

2 So by early December we expect to have
3 updated information on the accident analysis and
4 methodologies, and have essentially this portion of
5 the review resolved. So that's --

6 MEMBER BLEY: Steve?

7 MR. LYNCH: Yes?

8 MEMBER BLEY: It's Dennis Bley. I have
9 two questions.

10 MR. LYNCH: Yes.

11 MEMBER BLEY: One you jumped at me as you
12 said this, the other one I thought earlier. When you
13 guys have been doing your review, have you had access
14 to or in the FSAR anywhere, I haven't had a chance to
15 look through new documents, the process flow sheets
16 for the chemical side of the plant.

17 The other question is I think I just heard
18 you say the safety analysis document that's undocketed
19 is -- tell us more about that.

20 MR. LYNCH: Sure. So in order to support
21 our reviews of the application, SHINE has established
22 an electronic review portal to upload reference
23 materials to include different flow sheets and tables
24 and calculations and procedures and analyses that
25 support the docketed material in the FSAR.

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 And they have provided those in areas of
2 their accident analysis to include criticality safety
3 and chemical safety. And when it comes to this SSA,
4 so this is not information that the NRC staff would
5 typically expect to be docketed.

6 To provide a little bit of background, this
7 SSA previously was referred to as SHINE's integrated
8 safety analysis, or an ISA, that -- and what this
9 represents is a methodology that SHINE used to ensure
10 that they were identifying all of the potential accident
11 sequences and initiating events at the facility, be
12 able to root them, identify the most limiting event
13 within those that becomes a design-basis accident, and
14 also identify the necessary controls for that
15 particular accident sequence.

16 Now, for the --

17 MEMBER BLEY: So you're -- or --

18 MR. LYNCH: Sorry --

19 MEMBER BLEY: Or maybe the SHINE folk, from
20 our previous discussion, my understanding was that that
21 information Steve just described would also be
22 accessible to the members of the ACRS. Is that correct?

23 MR. LYNCH: So following the October 22nd
24 meeting, I have had some discussions with SHINE about
25 setting up a custom portal for the ACRS members to review

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 information. And one of the documents that we
2 highlighted that would most likely be of high interest
3 and value to the members in their review was this
4 document.

5 So following this meeting, what would I
6 like to do is start working with SHINE on getting this
7 portal up and running and start populating some of these
8 documents that are most relevant and of interest to
9 the members to help to support your review of the
10 application.

11 MEMBER BLEY: Okay. Thanks. That's
12 really important. Now, you didn't get to the process
13 flow sheets. Sorry I cut you off. Go ahead.

14 MR. LYNCH: Oh, well, I guess what I was
15 saying is with the -- so when it comes to our review
16 of the information that's in the SSA, some of the
17 requests for additional information, what's important
18 to us in terms of docketed materials is making sure
19 that SHINE has a sufficient description of the
20 methodology.

21 So what we want is, while we don't need
22 them to docket the SSA in its entirety, we want to make
23 sure that in the FSAR they describe what their process
24 was and what makes it acceptable so that based on our
25 review of that material we still have something in the

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 FSAR to say yes, this methodology is acceptable and
2 can be used going forward.

3 Should there be design changes at the
4 facility, the expectation is that SHINE will still
5 perform a 50/59 analysis to determine if a license
6 amendment is necessary to submit to the NRC staff.

7 And as part of either looking at a license
8 amendment or design changes that -- so let me step back.

9 If it's a license amendment the NRC staff could request
10 to look at the SSA as it's been updated to reflect that
11 amendment to ensure that it's being maintained.

12 And then should there be design changes
13 that screen out and do not require an amendment, hearing
14 inspection activities, NRC inspectors could look at
15 that SSA to ensure that it's being kept up to date with
16 changes of the facility.

17 For particular flow sheets I would need
18 to confirm with you that we had our reviewer look at
19 that information related to chemical safety. We did
20 request that SHINE did provide some documents in its
21 electronic reading room on chemical safety and I can
22 confirm with our reviewer what he had looked at.

23 But we do have a chemical safety RAI that
24 was developed to complete our review and make sure we
25 have what we need on that.

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 MEMBER BLEY: Okay. I was hoping that
2 would end up being up on that portal when we looked.

3 My past experience with chemical processing plant
4 safety is if you don't -- if the key information you
5 need to be able to really look at safety is in those
6 sheets.

7 MR. LYNCH: What I've done, though, is I've
8 made a note and we can work with SHINE on getting that
9 information for you.

10 MEMBER REMPE: Can you give us an idea of
11 the schedule of when you'll have this portal up and
12 running? Or at least a list of documents that would
13 be included in it?

14 MR. LYNCH: Sure. So some of us all need
15 to coordinate with SHINE on what it'll take to get this
16 updated. So I could talk to SHINE about their schedule
17 for that and I think as we're talking today I'm making
18 notes on what some of these documents are that are key.

19 Because one of the things that we want to
20 make sure is that, and I can let SHINE speak to this
21 as well since these are their documents, is that, you
22 know, the desire is to make sure that we are providing
23 the most high value documents to the members that is
24 organized and easy to access.

25 So I think we can have the portal up in

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 the short term and start, you know, start putting
2 together that list of documents. You know, I think
3 stemming out of that SSA is going to be important as
4 a starting point.

5 And we can work with you on the types of
6 documents that you're interested in, and maybe SHINE
7 might have a comment on this as well. But I think,
8 you know, the desire is to make sure that we're being
9 responsive the most safety significant concerns that
10 the ACRS members have, and not necessarily just
11 overwhelming you with all of the hundreds of thousands
12 of documents that SHINE has that are non-docketed.

13 MEMBER REMPE: So I hear that you're going
14 to try and get it to us soon. I understand that it
15 may not be complete, but I know in later slides you
16 grouped chapters and I'm not sure which grouping will
17 come to us first.

18 But maybe a preliminary list of some of
19 the supporting documents that you find most important
20 could be provided in a list by, within the next couple
21 of weeks or when?

22 MR. LYNCH: Sure. We can -- so following
23 this meeting, I'll have a conversation with SHINE and
24 let's see, within the next couple weeks maybe we can
25 make a goal of, where are we at, prior to maybe that

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 week of November 16th.

2 So prior to Thanksgiving we could work on
3 having that portal up and some initial documentation.

4 And what can be helpful too is maybe after we get those
5 initial documents, receive some feedback from the ACRS
6 members on the types of documents.

7 I can work with SHINE on highlighting for
8 each of the technical areas, maybe if there are certain
9 supporting documents that may be of interest. Maybe
10 there are certain documents related to seismic analysis
11 or aircraft impact that would be interest.

12 But we can, I'll work with SHINE on
13 identifying that.

14 MEMBER REMPE: A couple of weeks with the
15 list and some preliminary set of documents would be
16 awesome. Thank you.

17 CHAIRMAN BALLINGER: You know we need to,
18 I'm sure we, you know, we need to work through Chris
19 on this.

20 MR. BARTELME: And Steve, that's certainly
21 something SHINE can support. We can get that ACRS
22 specific reading groups quite quickly, and we'll get
23 a line of document types. So we can pool them and make
24 them available quickly.

25 MR. LYNCH: All right. So I am realizing

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 that we're starting to -- it is 12:40 so I'll speak
2 a little bit more quickly through these next slides
3 so that we are affording some time for closing comments
4 from the members.

5 So where we're at here is we have
6 established a 24-month review schedule to prepare the
7 safety evaluation for the SHINE application. And that
8 was established in April of this year.

9 So our goal is to complete our technical
10 review and have a complete safety evaluation prepared
11 by October of next year.

12 I talked through most of this so I'll go
13 through these slides relatively quickly. The main
14 difference is I wanted to highlight here between
15 construction permit and operating license application
16 reviews is, while the processes are similar, we are
17 looking at a FSAR and all of the information as presented
18 in there.

19 As more or less a fresh review of
20 information the difference then is with the
21 supplemental environmental impact statement, that is
22 more of a delta review that only new or significantly
23 different information is evaluated.

24 Per our processes, we are still going
25 through the ACRS subcommittee and full committee. And

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 then one of the differences we have here for our hearings
2 is there is no mandatory hearing for the issuance of
3 the operating license. There was only a mandatory
4 hearing of the construction permit stage.

5 There was a notice, an opportunity for
6 petition to leave and intervene in the SHINE
7 proceedings. There were no requests for a contested
8 hearing for this application.

9 Now as for the review methodology, similar
10 to the construction permit and for the operating license
11 application review, we are using NUREG-1537 as
12 augmented by interim staff guidance for aqueous
13 homogenous reactors and production facilities.

14 We are also using other guidance including
15 regulatory guides and industry standards to conduct
16 our review. Now, what's important about this, and I'm
17 sure as the members look at the SHINE final safety
18 analysis report and the NRC staff's SVR, our approach
19 to looking at SHINE's application of codes and standards
20 is really tailored to the commitments that they make
21 in the FSAR.

22 Recognizing that for the most part
23 particular codes and standards were developed for
24 specific technologies that SHINE is not, including
25 certain full cycle codes for criticality analysis,

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 codes for nuclear power reactors, codes for even
2 research reactors.

3 So recognizing that not all of these codes
4 and standards may be applicable in their entirety to
5 SHINE as we are conducting our review of the
6 application. We are paying particular attention to
7 the commitments SHINE makes to either using codes in
8 full or in part, and making sure that there is sufficient
9 justification for how they are using these codes.

10 So that is probably one of the significant
11 pieces of this review in ensuring that SHINE's adherence
12 to their commitments to codes and standards is also
13 supporting their principal design criterion identified
14 in the application.

15 For the review as we discussed, I think
16 at the internal ACRS on October 22nd, the NRC staff
17 had broken up the review into some different review
18 areas.

19 There were certain portions of the review
20 that we were able to move straight to preparation of
21 request for additional information. And then then
22 there were other areas, such as the I&C systems, the
23 accident analysis, criticality safety, that required
24 more in-depth coordination with SHINE.

25 And what one of the ways that we pride

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 leveraging communication between the NRC and SHINE was,
2 and continues to be, the use of regulatory audits to
3 further our understanding of technical gaps that have
4 been identified by the NRC staff and resolve those to
5 the extent practical of the regulatory audits so that
6 we can then issue focused requests for additional
7 information and reduce the need for follow-up RAIs.

8 When it comes the issuance of the
9 construction permit, again, the findings that we
10 basically made were making sure that we had enough
11 preliminary information to feel confident that SHINE
12 could go and construct their facility.

13 It did not authorize to have any material
14 on site. And essentially safety questions resulting
15 from the final design would be resolved with the
16 submission of the FSAR.

17 Now when it comes to issuing the operating
18 license, the things that we're going to be looking at
19 is making sure that we've met all of our safety
20 evaluation findings described in NUREG-1537, making
21 sure that again, some of these commitments that SHINE
22 had made as documented in appendix A to the construction
23 permit safety evaluation report have been addressed
24 or superseded and we have documentation of that to close
25 out those items.

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

(202) 234-4433

(202) 234-4433

1 And then when it comes to the specific
2 regulation that we're looking at in 10 C.F.R. 50.57
3 for the issuance of an operating license, what I'd like
4 to highlight here that's of particular importance as
5 the staff completes its safety evaluation report, one
6 of the other key findings that needs to be made is that
7 construction has been substantially completed.

8 And this is where the licensing review and
9 construction and construction inspection all come
10 together. So once the NRC staff has completed its
11 safety evaluation report, there is still another piece
12 where once SHINE has completed its construction of its
13 facility to include at a minimum the installation of
14 all safety related structure, systems, and components,
15 there is a notification that they will make to region
16 two, which is responsible for construction inspection.

17 And once that notification has been
18 received, region two will complete and verify that their
19 inspection activities are resolved and there will be
20 a letter from the region two administrator to the
21 director of the office of Nuclear Reactor Regulation.

22 And that is the inspection piece that leads
23 into the ultimate issuance of the operating license.

24 So I did want to highlight that there. So in addition
25 to completing our review of the application there is

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 the inspection piece that is necessary for the issuance
2 of the operating license.

3 When it comes to the technical areas of
4 the review, this is essentially the chapters of
5 NUREG-1537. I do note that there are some of these
6 areas that are not applicable to SHINE either at this
7 time or at all.

8 For example, looking at experimental
9 facilities, that's more common in research reactors,
10 not here for SHINE. Also SHINE is not converting from
11 HEU to LEU since they will be an LEU facility. So
12 chapter on uranium conversions is also not applicable.

13 So most of these topics were covered at
14 the construction permit stage. However, there are some
15 additional technical areas that were not presented in
16 the construction permit stage and will be presented
17 to the ACRS members for the first time.

18 Some of those that I in particular that
19 I'll highlight include a final emergency plan, a
20 physical security plan, discussions of operator
21 licensing start up, and human factors.

22 The one thing that I will note, a caveat
23 with human factors program, this is something that the
24 NRC staff is actively engaged with SHINE in to determine
25 the appropriateness of scope for human factors against

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 SHINE's design criteria.

2 We do have a regulatory audit on SHINE's
3 human factors, engineering program scheduled for
4 tomorrow where our goal coming out of that audit is
5 to have a clear idea of the necessity and scope of the
6 NRC staff's evaluation of the human factors program.

7 And I expect following that we'll have a clear path
8 forward on how that will be factored into the NRC staff's
9 review.

10 Going forward, I do want to highlight so
11 there's a number of audits that we've conducted that
12 have been very productive and resulted in significant
13 progress for this review related to instrumentation
14 and control systems, electrical power systems, accident
15 analysis and criticality safety, physical security,
16 and then as a result of the I&C audit we had back in
17 March, SHINE did submit a revised I&C chapter 7 as part
18 of its response to RAIs in that area in August of this
19 year.

20 And our staff is actively reviewing that
21 updated I&C chapter and I expect in the coming months
22 that we may have additional RAIs and may engage with
23 SHINE in future regulatory audits.

24 In terms of path forward on the licensing
25 review, I did mention that we do have RAIs that are

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 ready to be issued related to the accident analysis,
2 criticality safety, and chemical safety programs.
3 SHINE is also in the process of responding to previously
4 issues RAIs on external hazards and citing. And SHINE
5 has provided responses to other RAIs related to
6 instrumentation and control systems, their material
7 control and accounting program, as well as facility
8 descriptions.

9 There are some other technical areas that
10 we are looking to schedule audits likely in the December
11 and January timeframe. We need to work with SHINE on
12 specific dates for that and as well as NRC staff so
13 that we can have successful engagement.

14 Included in these are technical
15 specifications, operator licensing, fire protection,
16 and continued engagement on I&C systems. So with these
17 regulatory audits, in preparation for those, we will
18 put together technical topics that may for the basis
19 of future RAIs.

20 And coming out of these audits, the goal
21 is to have requests for additional information ready
22 for issuance to have resolved.

23 MEMBER BLEY: Hey, Steve?

24 MR. LYNCH: Yes.

25 MEMBER BLEY: I know there's going to be

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 discussion between you and Ron and maybe some others
2 about the topics at our upcoming meetings, but the first
3 one's coming in January. Which kind of things would
4 you even be prepared to talk about at that point?

5 MR. LYNCH: So that's actually something
6 I would like to talk about and need to do some internal
7 planning on how that's going to look. Probably where
8 we're at, some of the high level facility descriptions
9 are probably where we're mostly at. But I can skip
10 ahead to some of our proposals engaging with the ACRS.

11 One of the things that we have been
12 considering as the NRC staff is whether in order to
13 facilitate some of our discussions, if it makes sense
14 to have some of our first discussions with the ACRS
15 focused on those most safety significant items,
16 including the accident analysis, crit safety, chem
17 safety, how that relates to engineering safety
18 features, radiation and protection, looking at external
19 hazards, and grouping all of that together.

20 While we have some of that information
21 available now, we are expecting to get additional
22 information on SHINE hopefully closing out most of those
23 areas by early December, which would put us in a position
24 to have updated safety evaluation input likely in the
25 January, February timeframe.

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 So I do want to talk about with Ron and
2 Chris about what makes sense with some of these
3 presentations. Because one thing, while we can start
4 providing chapters, what I want to make sure is that
5 when we're sitting in front of the members that
6 recognizing some of the interconnectedness especially
7 with some of the safety significant portions, that as
8 questions come up we're able to fully respond to that
9 with the full context of completed other areas of the
10 review.

11 So that is something I do want to discuss.

12 I've got a meeting I believe Friday morning with Chris
13 and Ron to discuss that in more detail about how we
14 want to proceed in grouping these chapters and what
15 topics are best to start discussing.

16 I know there are some areas of particularly
17 MC&A that are wrapped up and probably ready for
18 discussion, doesn't make sense to talk about that ahead
19 of some of the other areas. We can figure out what
20 makes the most sense.

21 MEMBER BLEY: Thanks. I don't want to try
22 to pin it down right now but I think you can talk with
23 our guys and get that arranged.

24 Just off the top of my head, I'm thinking
25 under accident analysis, criticality safety, and

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 chemical safety, getting an as early as possible look
2 at the range of scenarios, if you will, that are being
3 considered, or events that are being considered --

4 MR. LYNCH: Yes.

5 MEMBER BLEY: -- would be a big help
6 because that could focus what comes later.

7 MR. LYNCH: Yes, absolutely. And I think
8 as part of our commitment to start getting documents
9 upload to an electronic reading room for the members,
10 having access to that SHINE safety analysis is going
11 to provide that full context of what were all of the
12 initiating events and scenarios considered by SHINE
13 that ultimately translated to the design basis
14 accidents and the controls that you see for the
15 facility.

16 And that we can have for the members in
17 the next couple weeks.

18 MEMBER BLEY: That's great.

19 MR. LYNCH: So I think this really -- so,
20 yes, I've got, so I think this does kind of conclude
21 the main remarks I have. I have got, yes, I have these
22 proposals of how we can group some of these chapters
23 based on safety significance and similar cross-cutting
24 areas between them that I think make sense to talk about.

25 As we prepare for these subcommittee

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 meetings I know there is a chart of looking at
2 identifying within each of these chapters what are the
3 most safety significant items we're focusing on and
4 we can certainly work with SHINE and with the ACRS on
5 aligning on what those areas are so that we can put
6 together those focused presentations for the members.

7 In terms of going forward, I do want to
8 make sure that we are getting information to the ACRS
9 in a timely manner so that you're able to have sufficient
10 time to review available materials the NRC staff
11 generates, and also that SHINE has prepared either as
12 docketed material or available in an electronic reading
13 room.

14 To the extent that we need to coordinate
15 with ACRS staff as well as members ahead of subcommittee
16 meetings to make sure that we're aligned on the key
17 focus areas, we are available for that and we look
18 forward to the continued engagement with the ACRS.

19 And I think with that that concludes the
20 presentation materials that I had.

21 CHAIRMAN BALLINGER: Thanks, Steve.
22 Okay, we're a little bit, well, we're almost there.
23 Questions from the members? I think we do have to go
24 back and open the public line for public comment.

25 So while we're getting that line open, do

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 we have comments from the members?

2 Silence is golden, I guess. Is the public
3 line open, Tom?

4 MALE PARTICIPANT: Public line is open for
5 comment.

6 CHAIRMAN BALLINGER: Okay. Are there any
7 folks out on the public line that would like to make
8 a comment? Please identify yourself and make your
9 comment.

10 Okay. I don't hear any comments. Okay,
11 this pretty much ends it, ends today's session. I think
12 the last couple of slides that Steve presented are,
13 at least from my standpoint, the critical ones because
14 we're having to hone in on the methodology, the path
15 forward for review by the committee, and we anticipate
16 that that will be established at the December P&P
17 meeting.

18 So that's our milestone. So I would
19 encourage members to provide feedback through Chris
20 to me, or both of us, related to this presentation and
21 anything else that you think is important for the
22 discussion in December.

23 And that pretty much ends it. So if there
24 are no other comments or questions from the members,
25 thank you very much for, to the SHINE people as well,

NEAL R. GROSS

COURT REPORTERS AND TRANSCRIBERS
1323 RHODE ISLAND AVE., N.W.
WASHINGTON, D.C. 20005-3701

1 for a great presentation, and for Steve and staff to
2 do the same.

3 So I think we are five minutes late, but
4 not so bad. So thank you very much and we are adjourned.

5 (Whereupon, the above-entitled matter went
6 off the record at 1:00 p.m.)

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25



SHINE Overview (Open Session)

Tracy Radel, VP of Engineering

Health. Illuminated.™




Outline (Open Session)


- SHINE Site Plan
- Construction Status
- Process Overview
- Technological Approach
- Safety Philosophy



Located in Janesville, WI



Site Plan






Site Rendering






Construction Status



Process Overview

1. Periodic solution preparation from LEU
2. Solution chemistry check and staging
3. Irradiation for 5.5 days
4. Extraction, purification, QC & packaging
5. Waste handling





Technological Approach

- Small systems: 125 kW, hundreds of times less power than isotope production reactors being used
 - Low source term—helps ensure safety of public and workforce
 - Decay heat per system < 1 kW within 5 hours
 - Minimizes waste nuclide generation compared to reactors
- Low enriched uranium (LEU) reusable target
 - Reduces waste
 - Product compatible with current supply chain
 - Eliminates need for HEU
- Driven by low-energy electrostatic accelerator
 - Fission essentially terminate shortly after driver turned off
- Multiple units and trains provide operational scalability and flexibility



Safety Philosophy

- Low decay heat, low pressure, low temperature system
 - Minimal stored energy
- Independent units limit common cause failures
- Operator actions are not required to mitigate the consequences of an accident
- In the event of an upset condition:
 - TSV reactivity protection system (TRPS) initiates trip of system
 - Two completely independent safety-related TSV dump valves open
 - Target solution gravity drains to the TSV dump tank (safe for all uranium concentrations)
 - Hydrogen concentration maintained below lower flammability limit (LFL) by off-gas system blowers
- Following UPS battery run time, entire plant is passively safe
 - 90 days without cooling: pool temperature rise is not more than 13°F
 - Nitrogen purge system for hydrogen control

Advisory Committee on Reactor Safeguards
Non-Power Production or Utilization Facility Subcommittee

SHINE Medical Technologies, LLC
Operating License Application Review

Steven Lynch, Senior Project Manager
Non-Power Production and Utilization Facility License Branch
Office of Nuclear Reactor Regulation
U.S. Nuclear Regulatory Commission
November 2020



Supporting Domestic ^{99}Mo Production

- NRC staff committed to efficient reviews of applications and inspections in accordance with the provisions of Title 10 of the *Code of Federal Regulations* (10 CFR)
- Licensing and oversight activities support U.S. national security interests and nuclear nonproliferation policy objectives of establishing a domestically-available and reliable supply of molybdenum-99 (^{99}Mo) without the use of highly-enriched uranium
- Applications include initial license and license amendment requests for facilities proposing to manufacture, irradiate, and process low enriched uranium and molybdenum targets
- Oversight activities focused on preparation for construction inspection of utilization and production facilities

Government Coordination and Legislation

- NRC staff coordinate other federal agencies, as well as local and state governments to support initial licensing application reviews
 - Department of Energy/National Nuclear Security Administration (NNSA)
 - Department of Homeland Security
- *American Medical Isotopes Production Act* provides for NRC and NNSA coordination on environmental reviews and the establishment of a uranium lease and takeback program
- *Nuclear Energy Innovation and Modernization Act* establishes three-year review period for non-power production or utilization facility initial licensing applications

Policy Work

- Non-Power Production or Utilization Facility License Renewal Final Rule
 - Final rule submitted to the Commission on June 17, 2019 (Agencywide Documents Access and Management System (ADAMS) Accession No. ML18031A001)
 - Implements Commission direction to streamline the license renewal process by establishing a more efficient, effective and focused regulatory framework
 - Uses innovative and transformative approaches to address existing shortcomings in the current regulations for non-power licensees, including establishing accident dose criterion and clarifying definitions
- Definition of Utilization Facility Direct Final Rule
 - Final rule published in Federal Register on October 17, 2014 (79 FR 62329)
 - Added definition of utilization facility to include SHINE accelerator-driven subcritical operating assemblies

Regulated Radioisotope Production Processes

- Target manufacturing
 - Preparation of low enriched uranium (LEU) targets for irradiation
- Target irradiation
 - Nuclear reactors
 - Subcritical operating assemblies
 - Accelerators
- Target processing
 - Hot cell separation of ^{99}Mo from irradiated LEU targets
- Medical uses of byproduct material
 - Generators for extracting technetium-99m from ^{99}Mo

Similarities to Existing Facilities

- Safety considerations comparable non-power reactors:
 - Fission heat removal
 - Decay heat generation
 - Fission gas release
 - Fission product buildup
 - Accident scenarios
- ...and fuel cycle facilities:
 - Target manufacturing
 - Radiation protection
 - Material processing
 - Criticality control
 - Chemical hazards

Responsibilities and Coordination

- The Division of Advanced Reactors and Non-Power Production and Utilization Facilities (DANU) is responsible, in part, for initial licensing activities associated with NPUFs licensed under 10 CFR Part 50.
- The following types of facilities may be licensed as commercial or research and development facilities under Sections 103 or 104 of the Atomic Energy Act, respectively:
 - Non-Power Reactors, including advanced reactor technologies
 - Subcritical Operating Assemblies
 - Production Facilities
- NRR relies on the expertise and support of other offices in the following technical areas to review medical radioisotope facility applications:
 - Emergency Planning
 - Physical Security
 - Environmental
 - Financial Qualifications
 - Material Control and Accounting
 - Accident Analysis
 - Chemical safety
 - Criticality Safety

Policy Work

- Non-Power Production or Utilization Facility License Renewal Final Rule
 - Final rule submitted to the Commission on June 17, 2019 (Agencywide Documents Access and Management System (ADAMS) Accession No. ML18031A001)
 - Implements Commission direction to streamline the license renewal process by establishing a more efficient, effective and focused regulatory framework
 - Uses innovative and transformative approaches to address existing shortcomings in the current regulations for non-power licensees, including establishing accident dose criterion and clarifying definitions
- Definition of Utilization Facility Direct Final Rule
 - Final rule published in Federal Register on October 17, 2014 (79 FR 62329)
 - Added definition of utilization facility to include SHINE accelerator-driven subcritical operating assemblies

SHINE Medical Technologies Background

- NRC received two-part construction permit application
 - Environmental Report (March 26, 2013)
 - Preliminary Safety Analysis Report (May 31, 2013)
- SHINE proposes to produce ^{99}Mo from fission of low enriched uranium target solution in Irradiation Facility consisting of 8 irradiation units
- ^{99}Mo recovered through irradiated target solution processing in Radioisotope Production Facility consisting of 3 hot cells
- Construction permit issued on February 29, 2016
- Construction commenced in September 2019
- Site: Janesville, WI

Periodic Reports on Permit Conditions

- Section 3.D.(1) of SHINE construction permit requires the submission of periodic reports to verify certain design elements related to nuclear criticality safety and radiation protection
 - Criticality accident alarm system
 - Nuclear criticality safety evaluations
 - Design information demonstrating shielding and occupancy times consistent with as low as reasonably achievable practices and dose requirements
- These reports generally supported potential construction inspection activities prior to the submission of an operating license application
- NRC staff reviewing current information final safety analysis report, as supplemented.

Licensing Overview: SHINE Irradiation Facility

- Irradiation facility houses eight subcritical irradiation units, which are comparable in power level and safety considerations to existing non-power reactors licensed under 10 CFR Part 50
- However, due to subcriticality, irradiation units did not meet the existing definition of utilization facility in 10 CFR 50.2 and could not be licensed under 10 CFR Part 70
- To align licensing process with potential hazards, NRC issued direct final rule modifying 10 CFR definition of utilization facility to include SHINE irradiation units
 - Published October 17, 2014
 - Effective December 31, 2014

Licensing Overview:

SHINE Radioisotope Production Facility

- Radioisotope Production Facility consists of three hot cells for ^{99}Mo separation and purification
- Based on batch size (i.e., greater than 100 grams), facility meets the definition of a production facility as defined in 10 CFR 50.2, “Definitions”
- While NRC has historically licensed production facilities, no such facilities currently operating
- Few previously-licensed facilities have conducted similar activities as SHINE
 - Cintichem (licensed under 10 CFR Part 70)
 - West Valley (licensed as a reprocessing facility)

SHINE General Licensing Approach

- SHINE requested single operating license under 10 CFR Part 50, “Domestic Licensing of Production and Utilization Facilities”
 - Irradiation units licensed as *utilization facilities*
 - Hot cells licensed as *production facility*
- Special nuclear material will be licensed under 10 CFR Part 70, “Domestic Licensing of Special Nuclear Material”
- Source material to be licensed under 10 CFR Part 40, “Domestic Licensing of Source Material”

SHINE Operating License Application

- SHINE submitted operating license application on July 17, 2019
- Operating license application accepted for review on October 8, 2019, noting the following areas that would require focused engagement with the NRC staff (ADAMS Accession No. ML19276D409):
 - Instrumentation and Control Systems
 - Accident Analysis and Methodologies
- Following public meetings and regulatory audits on these technical review areas, a schedule of 24 months was established in April 2020 (ADAMS Accession No. ML20114E315)

10 CFR Part 50 Licensing Process

- Similar review process for construction permit and operating license applications:
 - Acceptance and docketing review
 - Parallel safety and environmental reviews
 - Construction permit: preparation of safety evaluation report (SER) and environmental impact statement (EIS) (or environmental assessment)
 - Operating license: preparation of SER and supplemental EIS (or environmental assessment)
 - Request(s) for additional information, as needed
 - Advisory Committee on Reactor Safeguards (ACRS) review
 - Hearing(s)
 - Construction permit and operating license: potential for contested hearing(s)
 - Construction permit: mandatory hearing on sufficiency of staff safety and environmental reviews
 - Decision to grant or deny permit or license

NRC Safety Review Methodology

- Safety reviews for construction permit and operating license applications conducted in accordance with Commission's regulations
- The level of detail needed in a construction permit application and NRC staff's SER different than for combined operating license or operating license
 - The PSAR includes preliminary design of the facility, while the FSAR includes final design of the facility, as well as plans and programs not provided in PSAR
- Staff's review tailored to unique and novel technology described in construction permit application using appropriate regulatory guidance
 - NUREG-1537, "Guidelines for Preparing and Reviewing Applications for the Licensing of Non-Power Reactors"
 - Interim Staff Guidance Augmenting NUREG-1537
 - Other guidance (e.g., regulatory guides and industry standards) and engineering judgment used, as appropriate

Review Approach

In order to focus resources and efficiently complete the review of the SHINE operating license application, the staff is applying a tiered review strategy. Technical areas within the application are assigned review levels corresponding to scheduled milestones based on the complexity of the subject matter, availability of information, and maturity of design.

The review levels are defined as:

- **Level 1:** No clarification questions needed, information readily available, direct preparation of requests for additional information (RAIs)
- **Level 2:** Initial clarification questions needed, reference documents requested, and public meetings needed prior to developing RAIs
- **Level 3:** Fundamental scoping questions, clarification questions, public meetings, audits, and application supplements needed prior to developing RAIs
- Review Strategies:
 - Use of focused review groups
 - Leverage scaled review methodologies
 - Exchange of technical and licensing expertise
 - Establish clear responsibilities to ensure responsiveness and timeliness

Basis for Issuing Construction Permit

- The following findings must be made to issue a construction permit, based on 10 CFR 50.35:
 - Facility has been described, including the principal architectural and engineering criteria for the design
 - Further technical or design information may be reasonably left for later consideration in the FSAR
 - Safety features or components requiring research and development have been identified
 - Safety questions will be resolved prior to the completion of construction and the proposed facility can be constructed without undue risk to the health and safety of the public
- Staff's conclusions also based on the considerations in 10 CFR 50.40 and 50.50

Basis for Issuing Operating License

- The review of the operating license application is not a delta review of the construction permit application
- NRC staff consider commitments made by the applicant in Appendix A to the construction permit Safety Evaluation Report in preparing requests for additional information
- The following findings must be made to issue a construction permit, based on 10 CFR 50.57:
 - Construction has been substantially completed
 - Facility will operate in conformity with application and regulations
 - Reasonable assurance that operation will not endanger public health and safety
 - Applicant technically and financially qualified
 - Provisions of 10 CFR Part 140 satisfied
 - Issuance of license will not be inimical to common defense and security

NUREG-1537 Review Areas

1. The Facility/Introduction
2. Site Characteristics
3. Design of Structures, Systems, and Components
4. Facility Description
5. Coolant Systems
6. Engineered Safety Features
7. Instrumentation and Control
8. Electrical Power Systems
9. Auxiliary Systems
10. Experimental Facilities*
11. Radiation Protection and Waste Management
12. Conduct of Operations
 - Emergency Planning
 - Physical Security
 - Operator Licensing
 - Startup Plan
 - Human Factors
 - Quality Assurance
13. Accident Analysis
14. Technical Specifications
15. Financial Qualifications
16. Other License Considerations*
17. Decommissioning*
18. Uranium Conversions*
19. Environmental Review

*Not applicable to the SHINE operating license application

Review Status

Recent Milestones Achieved:

- Conducted instrumentation and control audit (March 2020)
- Conducted electrical power systems audit (May 2020)
- Conducted accident analysis and criticality safety audit (August 2020)
- Conducted security audit (September 2020)
- Received revised Instrumentation and Control Chapter 7 (August 2020)

Upcoming Milestones:

- Conducting human factors and startup plan audit (November 2020)
- Conducting technical specification audit (TBD)
- Conducting operating licensing audit (TBD)
- Conducting fire protection audit (TBD)
- Conducting additional instrumentation and control audit (TBD)

Review Schedule

In April 2020, staff established shortened 24-month review schedule and resource estimate of 22,000 hours based on availability of additional information on SHINE's accident analysis and instrumentation and control (I&C) systems

Milestone	Est. Completion Date	Actual Completion Date	Status
Acceptance and Docketing of Application	October 2019	October 2019	Complete
ACRS Subcommittee Planning Meeting	October 22, 2020	TBD	Pending
ACRS Subcommittee Meeting	November 4, 2020	TBD	Pending
Publication of Draft EIS Supplement	January 2021	TBD	Pending
Publication of Final EIS Supplement	August 2021	TBD	Pending
Draft Safety Evaluation Complete	July 2021	TBD	Pending
ACRS Full Committee Meeting	September 2021	TBD	Pending
Final Safety Evaluation Report Complete	September 2021	TBD	Pending
Final Determination on Issuance of Operating License	October 2021	TBD	Pending

Project Risks

Technical Risks

Risk	Risk Level	Mitigation
SHINE development of I&C systems delays due to revision of FSAR in August 2020	Moderate	Engagement with SHINE to align on what information is most safety-significant

Schedule Risks

Risk	Risk Level	Mitigation
Potential design changes, including development of I&C systems	Moderate	Outside of NRC staff control
Revision of physical security plan	Moderate	Staff working with SHINE on receiving revision to avoid unnecessary RAIs
Staff turnover following closeout of review areas ahead of overall project completion	Moderate	1. Closeout ACRS actions within 90 days of subcommittee meetings 2. Identify and resolve legal questions early
SHINE timeliness in responding to RAIs	Moderate	Staff coordination with SHINE to ensure draft RAIs are well-understood and reasonable response timeframes are established
SHINE completion of construction	Moderate	Outside of NRC staff control

Cost Risks

- *None at this time*

Policy Risks

- *None at this time*

ACRS Subcommittee Engagement

- Present on technical topics based on safety-significance and relation to other topics
- Present on technical topics only after NRC staff has resolved all open items with licensee
- Staff propose three subcommittee meetings, organized by the safety-significance of technical areas, covering all chapters of the application
 - Prior to scheduled subcommittee meetings, staff will identify most safety significant areas within each topic that merit focused discussion
 - For areas that don't require focused technical discussion, staff and applicant will be prepared to answer questions, but may not have prepared materials

ACRS Subcommittee Engagement (Continued)

- Subcommittee Topic Grouping 1:
 - Facility Description (Chapters 1, 4)
 - Accident Analysis (Chapter 13)
 - Criticality Safety (Chapter 6, 13)
 - Chemical Safety (Chapter 4, 13)
 - Engineered Safety Features (Chapter 6)
 - Site Characteristics and External Hazards (Chapters 2, 3)
 - Radiation Protection and Waste Management (Chapter 11)
- Subcommittee Topic Grouping 2:
 - Instrumentation and Control Systems (Chapter 7)
 - Electrical Power Systems (Chapter 8)
 - Coolant Systems (Chapter 5)
 - Conduct of Operations (Chapter 12)
 - Emergency Planning
 - Physical Security
 - Operator Licensing
 - Startup Plan
 - Human Factors
 - Quality Assurance
- Subcommittee Topic Grouping 3:
 - Technical Specifications (Chapter 14)
 - Follow-up items

Success Strategies

- Early and frequent engagement with SHINE
 - Leverage use of electronic reading room, audits, public meetings, and clarification calls to improve understanding of application
- Leverage Technology
 - Use of electronic reading rooms, virtual meetings
- Communication at all levels
 - Communicate and align on key messages and review approaches across offices and at all organizational levels
 - Communicate review status and key milestones with Advisory Committee on Reactor Safeguards